$1.36
$7.30
52-Week Range
At a Glance
AI-generatedQ32 Bio Inc.
8-K
Q32 Bio Inc. entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. on March 27, 2026, establishing an at-the-market offering program to sell up to $14,200,000 of its common stock. This agreement provides the company with a flexible mechanism to raise capital from time to time at its discretion.$79M
Market Cap
$53M
Revenue
$29M
Net Income
Employees28
Fundamentals
How The Business Makes Money
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001661998
ISINUS7469641051
CUSIP746964105
Phone781 999 0232
Address830 Winter Street, Waltham, MA, 02451, US
SEC EDGAR